Hospital
Russell County Hospital
Russell County Hospital was paid $20.75M by Medicaid between Jan 2018 and Dec 2024, across 176 billing codes. Its largest line is 99283, emergency room visit (moderate) — 11% of everything it billed.
33Billing provider infoRUSSELL COUNTY HOSPITAL
RUSSELL SPRINGS, KY 42642
RUSSELL SPRINGS, KY 42642
33aNPI1013954437assigned 06/02/2006
33bProvider typeCritical Access Hospital
28Total paid$20.75M
24GClaims454,280
24DCodes billed176
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Kentucky
Rank by total paid#5 of 16
Median peer was paid$11.73M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,999 | $2.08M | |
| 2019 | 60,556 | $2.50M | |
| 2020 | 56,427 | $2.34M | |
| 2021 | 70,542 | $3.18M | |
| 2022 | 75,968 | $3.58M | |
| 2023 | 74,468 | $3.90M | |
| 2024incomplete | 58,320 | $3.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 19,952 | 17,084 | $2.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 12,309 | 10,384 | $2.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.8% | 9,816 | 7,101 | $2.04M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.2% | 3,828 | 3,234 | $1.50M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.4% | 7,932 | 2,581 | $905K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 2,378 | 1,916 | $754K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.0% | 10,179 | 7,707 | $628K |
| 80053 | Comprehensive metabolic panel | 2.8% | 46,248 | 22,558 | $576K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.7% | 16,843 | 13,425 | $559K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.3% | 21,559 | 11,245 | $479K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 5,250 | 2,234 | $453K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 8,186 | 3,696 | $447K |
164 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 9,710 | $444K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 7,948 | $387K |
| 71250 | 1.8% | 1,021 | $372K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.8% | 1,492 | $368K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 4,423 | $310K |
| 80050 | General health panel | 1.4% | 4,264 | $283K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 24,982 | $256K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 4,482 | $244K |
| 80306 | 1.2% | 6,013 | $242K | |
| 71045 | Radiologic examination, chest; single view | 1.0% | 4,300 | $216K |
| 84484 | <1% | 5,640 | $202K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,526 | $160K |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,150 | $149K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,756 | $147K |
| 83605 | <1% | 2,289 | $133K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 433 | $130K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,688 | $128K |
| 73630 | <1% | 1,568 | $117K | |
| 83880 | <1% | 3,135 | $113K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,472 | $111K |
| 85379 | <1% | 3,236 | $110K | |
| 87430 | <1% | 6,903 | $108K | |
| 82553 | <1% | 4,429 | $102K | |
| 80061 | Lipid panel | <1% | 7,938 | $100K |
| 97161 | <1% | 2,103 | $99K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,930 | $95K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 745 | $93K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 180 | $93K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,322 | $92K |
| 72100 | <1% | 1,073 | $92K | |
| 82550 | <1% | 4,843 | $91K | |
| 82607 | <1% | 2,970 | $90K | |
| 73130 | <1% | 1,100 | $85K | |
| 73030 | <1% | 1,178 | $85K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,435 | $84K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 687 | $84K |
| 87077 | <1% | 5,188 | $83K | |
| 81001 | <1% | 10,581 | $82K | |
| 84703 | <1% | 4,463 | $80K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,099 | $79K |
| 73562 | <1% | 1,330 | $76K | |
| 73610 | <1% | 931 | $71K | |
| 82565 | <1% | 1,316 | $67K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,936 | $59K |
| 82150 | <1% | 4,113 | $59K | |
| 83690 | <1% | 4,492 | $57K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,359 | $54K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 160 | $49K |
| 82043 | <1% | 1,441 | $48K | |
| 84439 | <1% | 2,348 | $47K | |
| 87420 | <1% | 1,142 | $45K | |
| 85730 | <1% | 3,761 | $45K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 548 | $44K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,339 | $43K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 89 | $43K |
| 85610 | <1% | 5,348 | $41K | |
| 87186 | <1% | 2,481 | $41K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,628 | $40K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 224 | $39K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 444 | $38K |
| 83735 | <1% | 3,510 | $31K | |
| 87428 | <1% | 444 | $30K | |
| 87522 | Neg quan hep c or qual rna | <1% | 487 | $28K |
| 73110 | <1% | 338 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,002 | $26K |
| J2704 | Injection, propofol, 10 mg | <1% | 849 | $25K |
| 86140 | <1% | 1,305 | $25K | |
| 82728 | <1% | 1,028 | $24K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,332 | $22K |
| 93971 | <1% | 166 | $22K | |
| 87070 | <1% | 780 | $21K | |
| 87040 | <1% | 1,004 | $21K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 923 | $19K |
| 72040 | <1% | 219 | $17K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,315 | $16K |
| 86703 | <1% | 430 | $16K | |
| 97035 | <1% | 732 | $15K | |
| 74018 | <1% | 249 | $14K | |
| 12001 | <1% | 86 | $13K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 94 | $13K |
| 87205 | <1% | 1,172 | $13K | |
| 82803 | <1% | 376 | $12K | |
| 82948 | <1% | 1,394 | $11K | |
| 83540 | <1% | 841 | $10K | |
| 85652 | <1% | 1,119 | $10K | |
| 82746 | <1% | 275 | $10K | |
| 97032 | <1% | 371 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 674 | $9K |
| 85027 | <1% | 938 | $8K | |
| 87081 | <1% | 388 | $8K | |
| 76536 | <1% | 48 | $8K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 767 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 38 | $7K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 761 | $7K |
| 80076 | <1% | 360 | $7K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 439 | $6K |
| 80074 | <1% | 130 | $6K | |
| 93225 | <1% | 30 | $6K | |
| 87075 | <1% | 149 | $6K | |
| 83550 | <1% | 449 | $6K | |
| 82570 | <1% | 1,291 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $5K |
| 81003 | <1% | 567 | $5K | |
| 96376 | <1% | 162 | $5K | |
| 83921 | <1% | 324 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 872 | $4K |
| 85007 | <1% | 786 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 221 | $4K |
| 72141 | <1% | 15 | $4K | |
| 36600 | <1% | 309 | $4K | |
| 97124 | <1% | 106 | $4K | |
| 81596 | <1% | 72 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 83 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 121 | $3K |
| 72072 | <1% | 34 | $3K | |
| 84145 | <1% | 96 | $3K | |
| 86308 | <1% | 151 | $3K | |
| 73090 | <1% | 27 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 70 | $2K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $2K |
| 0031A | <1% | 131 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 356 | $2K |
| 97012 | <1% | 55 | $2K | |
| 71271 | <1% | 51 | $2K | |
| 87902 | <1% | 14 | $2K | |
| 84550 | <1% | 104 | $2K | |
| 84702 | <1% | 48 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 31 | $2K |
| 90714 | <1% | 206 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 49 | $1K |
| 73590 | <1% | 20 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 117 | $1K |
| 73080 | <1% | 13 | $1K | |
| 84481 | <1% | 57 | $1K | |
| 86038 | <1% | 77 | $982.99 | |
| 73502 | <1% | 13 | $936.22 | |
| 76641 | <1% | 14 | $914.15 | |
| 86141 | <1% | 30 | $843.73 | |
| 74019 | <1% | 12 | $816.56 | |
| 87045 | <1% | 12 | $728.20 | |
| 86705 | <1% | 29 | $702.22 | |
| 86704 | <1% | 54 | $584.78 | |
| 86706 | <1% | 52 | $507.98 | |
| 86200 | <1% | 42 | $496.42 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 42 | $484.68 |
| 84520 | <1% | 32 | $448.34 | |
| 82962 | <1% | 202 | $418.98 | |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 65 | $418.75 |
| 93243 | <1% | 15 | $413.19 | |
| 87340 | <1% | 39 | $398.27 | |
| 87046 | <1% | 12 | $379.12 | |
| 82105 | <1% | 17 | $372.31 | |
| 86708 | <1% | 28 | $330.70 | |
| 86160 | <1% | 12 | $317.28 | |
| 86709 | <1% | 29 | $307.38 | |
| 86780 | <1% | 13 | $271.48 | |
| 87899 | <1% | 22 | $258.82 | |
| 86803 | <1% | 13 | $258.55 | |
| 87209 | <1% | 13 | $238.96 | |
| 82274 | <1% | 24 | $221.84 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 114 | $206.59 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 17 | $165.00 |
| 87177 | <1% | 13 | $118.76 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 20 | $81.83 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNORRIS, NEQUILA (DIR OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Russell County Hospital | Russell Springs, KY | $1.71M |
| Russell County Hospital | Russell Springs, KY | $1.02M |
| Russell County Hospital | Russell Springs, KY | $428K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.